These agents have specific targets in various types of cancer, such as blocking Bruton’s tyrosine kinase (BTK) in mantle cell lymphoma, targeting mutant EGFR in NSCLC, or inhibiting ErbB2 in HER2-positive breast cancer, and Waldenström macroglobulinemia. Here, BTK is linked to cancer.